Pediatric Emergencies — Part 2: Pediatric Respiratory Emergencies
Croup scoring and management, bronchiolitis evaluation and supportive care, acute asthma severity classification and stepwise treatment, anaphylaxis recognition and epinephrine dosing, and foreign body aspiration management.
1. Croup (Laryngotracheobronchitis)
Croup is the most common cause of acute upper airway obstruction in children aged 6 months to 6 years, with a peak incidence at 1 to 2 years of age. It is caused by viral infection (most commonly parainfluenza types 1 and 3, but also RSV, influenza, adenovirus, and human metapneumovirus) producing inflammation and edema of the subglottic airway. The hallmark triad of barky (seal-like) cough, inspiratory stridor, and hoarseness is usually preceded by 1-3 days of upper respiratory symptoms. Symptoms characteristically worsen at night.1 2
1.1 Westley Croup Severity Score
The Westley Croup Score is the most widely validated and utilized clinical scoring system for assessing croup severity. Scores range from 0 to 17, with higher scores indicating more severe disease.1
| Feature | 0 Points | 1 Point | 2 Points | 3 Points | 4 Points | 5 Points |
|---|---|---|---|---|---|---|
| Chest wall retractions | None | Mild | Moderate | Severe | — | — |
| Stridor | None | With agitation | At rest | — | — | — |
| Air entry | Normal | Decreased | Markedly decreased | — | — | — |
| Cyanosis | None | — | — | — | With agitation | At rest |
| Level of consciousness | Normal | — | — | — | — | Disoriented |
Severity Classification:
| Score | Severity | Clinical Features |
|---|---|---|
| 0–2 | Mild | Occasional barky cough; no stridor at rest; no or mild retractions |
| 3–5 | Moderate | Frequent barky cough; stridor at rest; retractions at rest; no agitation |
| 6–11 | Severe | Frequent barky cough; prominent stridor at rest; marked retractions; agitation or lethargy |
| 12–17 | Impending respiratory failure | Diminished stridor (may indicate critical obstruction); lethargy; markedly decreased air entry; cyanosis |
1.2 Croup Management Ladder
| Severity | Treatment | Dose / Details |
|---|---|---|
| Mild (0–2) | Dexamethasone (single dose) | 0.6 mg/kg PO/IM (max 10 mg); PO preferred if tolerated |
| Supportive care | Cool mist humidification (unproven but widely used); comfort measures; may discharge if improved after observation | |
| Moderate (3–5) | Dexamethasone (single dose) | 0.6 mg/kg PO/IM (max 10 mg) |
| Nebulized epinephrine | Racemic epinephrine 0.5 mL of 2.25% solution in 3 mL NS via nebulizer, OR L-epinephrine 0.5 mL/kg of 1:1,000 (max 5 mL) via nebulizer | |
| Observation | Observe for minimum 2-4 hours after nebulized epinephrine for rebound (return of symptoms after epinephrine effect wanes at 1-2 hours) | |
| Severe (6–11) | Dexamethasone (single dose) | 0.6 mg/kg PO/IM (max 10 mg); IM if unable to take PO |
| Nebulized epinephrine | Same dose as above; may repeat every 15-20 minutes for up to 3 doses if needed | |
| Supplemental oxygen | Blow-by or humidified oxygen as tolerated; avoid agitating the child (agitation worsens obstruction) | |
| Admission | Admit if persistent stridor at rest after treatment; multiple epinephrine nebulizations required | |
| Impending failure (12–17) | All above interventions | — |
| Prepare for advanced airway | Call anesthesia/ENT; prepare for intubation with ETT 0.5-1 mm smaller than age-predicted size | |
| Heliox | 70:30 or 80:20 helium-oxygen mixture may reduce work of breathing (if available, not requiring >30% FiO2) |
1.3 Key Points
- Dexamethasone 0.6 mg/kg is the single most effective treatment for croup at all severity levels; benefit seen within 2-4 hours and lasts 24-72 hours
- Lower doses (0.15 mg/kg) have shown comparable efficacy in some studies for mild-moderate croup, but 0.6 mg/kg remains the standard recommended dose
- Nebulized epinephrine provides rapid temporary relief (onset 10-30 minutes) but does not shorten disease course; observe for rebound
- Antibiotics are not indicated — croup is virtually always viral
- Radiographs are not routinely needed — the classic “steeple sign” on AP neck film has poor sensitivity and specificity; obtain imaging only if the diagnosis is uncertain or foreign body is suspected
- Consider bacterial tracheitis if a child with croup-like symptoms has high fever, toxic appearance, and fails to respond to standard therapy1 2
2. Bronchiolitis
Bronchiolitis is the most common lower respiratory tract infection in infants, typically affecting children younger than 2 years (peak 2-6 months). Respiratory syncytial virus (RSV) is responsible for 50-80% of cases, with other causes including rhinovirus, human metapneumovirus, parainfluenza, influenza, and adenovirus. The clinical guideline emphasizes supportive care, as numerous trials have demonstrated no benefit from bronchodilators, corticosteroids, or antibiotics in typical bronchiolitis.3 4
2.1 Clinical Diagnosis and Assessment
Bronchiolitis is a clinical diagnosis. Key features include:
- Age typically <2 years (most commonly <12 months)
- Preceded by 2-4 days of URI symptoms (rhinorrhea, cough, low-grade fever)
- Progressive cough, tachypnea, wheezing, crackles, increased work of breathing
- Difficulty feeding due to respiratory distress
Severity Assessment:
| Severity | Clinical Features |
|---|---|
| Mild | SpO2 ≥92%; feeding well (taking >50% usual feeds); mild tachypnea; mild or no retractions; comfortable and alert |
| Moderate | SpO2 90-92%; reduced feeding (taking 50-75% usual feeds); moderate tachypnea; subcostal/intercostal retractions; some agitation |
| Severe | SpO2 <90%; unable to feed or taking <50% usual feeds; marked tachypnea or apnea; severe retractions with nasal flaring and grunting; lethargic or irritable |
2.2 Management: What Is Recommended
| Intervention | Details |
|---|---|
| Nasal suctioning | Gentle bulb or mechanical suction of the nasopharynx to clear secretions; most effective before feeds and before respiratory assessment |
| Supplemental oxygen | Indicated if SpO2 persistently <90%; target SpO2 ≥90% (not 94-98%); avoid continuous pulse oximetry in stable infants as transient desaturations may trigger unnecessary interventions |
| High-flow nasal cannula (HFNC) | 2 L/kg/min (max ~20 L/min in infants); provides heated, humidified oxygen with low-level CPAP effect; decreases work of breathing; consider for moderate-severe bronchiolitis with persistent hypoxia or increased work of breathing |
| Hydration and feeding support | Maintain hydration via oral, NG, or IV route; small frequent feeds; IV maintenance fluids (isotonic) if oral intake insufficient |
| Antipyretics | Acetaminophen or ibuprofen (>6 months) for fever causing discomfort |
2.3 Management: What Is NOT Recommended
The following interventions have been studied in multiple randomized controlled trials and are specifically not recommended for routine use in bronchiolitis.3 4
| Intervention NOT Recommended | Evidence |
|---|---|
| Albuterol / salbutamol | Multiple RCTs and meta-analyses show no improvement in disease severity, hospitalization rates, or duration of illness; may cause tachycardia and tremor |
| Epinephrine (nebulized) | No sustained benefit in inpatient setting; may have marginal short-term effect in ED but does not reduce admission rate |
| Systemic corticosteroids | No benefit demonstrated in multiple large RCTs; no reduction in admission, length of stay, or disease severity |
| Hypertonic saline (3%) | Conflicting evidence; 2023 updated guideline notes insufficient evidence to recommend for ED use; may have modest benefit for inpatients (NNT ~6 for reducing LOS by 1 day) but not routinely recommended |
| Antibiotics | Not indicated unless documented secondary bacterial infection (e.g., AOM, UTI, pneumonia) |
| Chest physiotherapy | No benefit; may worsen distress |
| Chest radiograph (routine) | Not recommended for typical bronchiolitis; increases inappropriate antibiotic use; obtain only if diagnostic uncertainty or suspected complication |
| Viral testing (routine) | Not required for management; may be useful for cohorting in hospitalized patients |
2.4 Admission Criteria
| Criterion | Details |
|---|---|
| Persistent hypoxia | SpO2 <90% despite nasal suctioning and supplemental oxygen |
| Significant respiratory distress | Moderate-severe retractions, tachypnea, nasal flaring, grunting |
| Apnea | Any witnessed apneic episode |
| Dehydration | Unable to maintain adequate oral intake |
| High-risk patient | Age <12 weeks; premature birth (<37 weeks, especially <32 weeks); hemodynamically significant congenital heart disease; chronic lung disease; immunodeficiency; neuromuscular disease |
| Unreliable follow-up | Caregiver unable to recognize worsening; no access to emergency care |
2.5 Discharge Criteria
- Maintaining SpO2 ≥90% on room air for ≥4 hours (including during sleep if inpatient)
- Adequate oral intake (≥75% of usual volume)
- Respiratory rate and work of breathing at or near baseline
- Caregiver comfortable with suctioning and monitoring
- Follow-up arranged within 24-48 hours3 4
3. Acute Asthma Exacerbation
Asthma is the most common chronic disease of childhood, affecting approximately 6-8% of children worldwide. Acute exacerbations are among the most frequent pediatric emergency department presentations. Rapid severity assessment and a stepwise escalation approach to bronchodilator, corticosteroid, and adjunctive therapy can prevent respiratory failure and reduce the need for mechanical ventilation.5 6
3.1 Acute Severity Classification
| Parameter | Mild | Moderate | Severe | Life-Threatening |
|---|---|---|---|---|
| Breathlessness | Walking; can lie down | Talking; prefers sitting | At rest; hunched forward | Unable to speak |
| Talks in | Sentences | Phrases | Words | Cannot speak |
| Alertness | May be agitated | Usually agitated | Usually agitated | Drowsy or confused |
| Respiratory rate | Increased | Increased | Often >30/min | Paradoxical breathing |
| Accessory muscle use | Usually not | Usually | Usually | Paradoxical thoracoabdominal movement |
| Wheeze | Moderate, end-expiratory | Loud, throughout expiration | Loud, throughout inspiration and expiration | Absent (“silent chest”) |
| Heart rate | <100 | 100–120 | >120 | Bradycardia |
| SpO2 (on room air) | >95% | 90–95% | <90% | <90% |
| PEF (if obtainable) | >70% predicted | 50–70% predicted | <50% predicted | <25% predicted |
| Pulsus paradoxus | Absent (<10 mmHg) | May be present (10-25 mmHg) | Often present (>25 mmHg) | Absence suggests respiratory muscle fatigue |
3.2 Stepwise Management of Acute Asthma
Step 1: All Severities — Initial Assessment and Treatment
| Intervention | Dose / Details |
|---|---|
| Albuterol (salbutamol) nebulization | 0.15 mg/kg (min 2.5 mg, max 5 mg) every 20 minutes for 3 doses in the first hour; OR continuous nebulization 0.5 mg/kg/hr (max 15 mg/hr) for severe exacerbation |
| Albuterol MDI (mild-moderate) | 4-8 puffs via spacer every 20 min for up to 3 doses; each puff = 90 mcg |
| Oxygen | Maintain SpO2 ≥92-94%; use blow-by or nasal cannula as tolerated |
Step 2: Moderate-Severe — Add Ipratropium and Systemic Steroids
| Intervention | Dose / Details |
|---|---|
| Ipratropium bromide | 0.25 mg (<20 kg) or 0.5 mg (≥20 kg) nebulized with albuterol every 20 min for 3 doses in the first hour only; benefit limited to first 1-2 hours, not recommended after initial treatment |
| Systemic corticosteroids | Dexamethasone 0.6 mg/kg PO/IM (max 16 mg) × 1-2 doses (evidence supports single dose non-inferiority to 5-day prednisone for most patients); OR Prednisone/Prednisolone 1-2 mg/kg/day PO (max 60 mg) for 3-5 days |
Step 3: Severe — IV Access and Escalation
| Intervention | Dose / Details |
|---|---|
| Continue continuous albuterol | 0.5 mg/kg/hr (max 15 mg/hr) via continuous nebulization |
| IV magnesium sulfate | 25-75 mg/kg IV (commonly 50 mg/kg; max 2 g) infused over 20-30 minutes; acts as smooth muscle relaxant; most effective when given early in severe exacerbation; monitor for hypotension |
| Reassess frequently | If not improving → proceed to Step 4 |
Step 4: Refractory/Life-Threatening — ICU-Level Interventions
| Intervention | Dose / Details |
|---|---|
| IV terbutaline | Loading dose: 10 mcg/kg IV over 10 minutes, then continuous infusion 0.1-10 mcg/kg/min; titrate to effect; monitor continuous ECG (risk of arrhythmia), lactate, potassium |
| IV aminophylline | Loading dose: 5-7 mg/kg IV over 30 minutes (omit if patient already on theophylline); maintenance: 0.5-1 mg/kg/hr continuous infusion; target serum level 10-15 mcg/mL; narrow therapeutic index — monitor for nausea, vomiting, seizures, arrhythmia |
| IV epinephrine | 0.01 mg/kg (1:10,000) IV/IO if near-arrest; or epinephrine drip 0.1-1 mcg/kg/min |
| Non-invasive ventilation (BiPAP) | May reduce work of breathing and avoid intubation; settings: IPAP 10-16 cmH2O, EPAP 5-8 cmH2O; requires cooperative patient |
| Intubation (last resort) | Ketamine 1-2 mg/kg IV for induction (bronchodilator properties); use largest ETT tolerated to reduce resistance; post-intubation: permissive hypercapnia strategy; low RR (8-12), long expiratory time (I:E 1:4-1:5), avoid air-trapping |
| Inhaled anesthetics | Sevoflurane or isoflurane via ventilator circuit in ICU — potent bronchodilators for truly refractory status asthmaticus |
3.3 Disposition
| Response | Disposition |
|---|---|
| Good response — symptoms resolved, PEF >70%, SpO2 >94%, tolerating PO | Discharge with: albuterol MDI + spacer every 4-6 hrs; corticosteroid (dexamethasone or short course prednisone); written asthma action plan; follow-up in 1-5 days |
| Incomplete response — persistent symptoms, PEF 50-70%, requiring albuterol >q2h | Admit to floor; continue bronchodilators q1-2h; systemic steroids; reassess for ICU transfer if worsening |
| Poor response / life-threatening — severe symptoms, PEF <50%, altered consciousness, cyanosis | Admit to ICU; continuous nebulization; consider IV magnesium, terbutaline, aminophylline; prepare for possible intubation |
4. Anaphylaxis
Anaphylaxis is a severe, potentially fatal systemic allergic reaction that occurs rapidly (usually within minutes to hours) after exposure to an allergen. In children, the most common triggers are foods (peanut, tree nuts, cow’s milk, egg, shellfish), insect stings, and medications. Rapid recognition and immediate intramuscular epinephrine administration are the cornerstones of treatment. Delays in epinephrine are associated with increased morbidity and mortality.7 8
4.1 Diagnostic Criteria
Anaphylaxis is highly likely when any ONE of the following criteria is met:
Acute onset (minutes to hours) of skin/mucosal involvement (urticaria, flushing, angioedema) PLUS at least one of:
- Respiratory compromise (dyspnea, wheeze, stridor, hypoxia)
- Hypotension or end-organ dysfunction (collapse, syncope, incontinence)
Two or more of the following occurring rapidly after exposure to a likely allergen:
- Skin/mucosal involvement
- Respiratory compromise
- Hypotension or associated symptoms
- Persistent GI symptoms (crampy abdominal pain, vomiting)
Hypotension after exposure to a known allergen for that patient (age-specific: SBP <70 mmHg for 1 month-1 year, <70 + [2 × age] for 1-10 years, <90 mmHg for >10 years)
4.2 Treatment
| Priority | Intervention | Dose / Details |
|---|---|---|
| 1 | Epinephrine IM | 0.01 mg/kg of 1:1,000 (1 mg/mL) IM into anterolateral thigh; max 0.3 mg for children <30 kg; max 0.5 mg for children ≥30 kg; may repeat every 5-15 minutes as needed; this is the FIRST and MOST IMPORTANT treatment |
| 2 | Position | Supine with legs elevated if hypotensive (Trendelenburg); if vomiting or dyspneic, allow position of comfort; do NOT sit or stand the patient up abruptly (risk of empty ventricle syndrome/sudden death) |
| 3 | Oxygen | High-flow oxygen via non-rebreather mask (10-15 L/min) |
| 4 | IV fluid bolus | 20 mL/kg NS IV bolus if hypotensive; repeat as needed (may require 40-60 mL/kg in severe anaphylactic shock) |
| 5 | Albuterol | 2.5-5 mg nebulized for persistent bronchospasm not responsive to epinephrine |
| 6 | H1 antihistamine | Diphenhydramine 1 mg/kg IV/IM/PO (max 50 mg) — adjunct only, does NOT treat hypotension or airway obstruction |
| 7 | H2 antihistamine | Ranitidine 1 mg/kg IV (max 50 mg) or famotidine 0.25 mg/kg IV (max 20 mg) — adjunct |
| 8 | Corticosteroids | Methylprednisolone 1-2 mg/kg IV (max 125 mg) or dexamethasone 0.6 mg/kg (max 10 mg) — may help prevent biphasic reaction; onset too slow for acute treatment |
| 9 | Glucagon (beta-blocker refractory) | 20-30 mcg/kg IV (max 1 mg) over 5 min; for patients on beta-blockers who fail to respond to epinephrine |
| 10 | Epinephrine infusion (refractory shock) | 0.1-1 mcg/kg/min IV; titrate to blood pressure and heart rate |
4.3 Observation Period
- Observe for 4-6 hours minimum after resolution of symptoms to monitor for biphasic reactions (recurrence of symptoms without re-exposure, occurring in 1-20% of cases, typically within 1-72 hours)
- Extended observation (12-24 hours) is recommended for:
- Severe initial reaction (requiring multiple doses of epinephrine, hypotension, respiratory failure)
- History of prior biphasic reaction
- Previous severe anaphylaxis
- Delayed presentation (>4 hours from exposure to treatment)
- Poor access to emergency care
4.4 Discharge Requirements
- Prescribe epinephrine auto-injector (0.15 mg for 7.5-25 kg; 0.3 mg for >25 kg) and demonstrate proper technique
- Provide written anaphylaxis action plan
- Instruct on allergen avoidance
- Recommend medical alert identification
- Refer to allergist/immunologist for formal allergy testing
- Consider short course of oral corticosteroid (3-5 days) and antihistamine to reduce risk of biphasic reaction7 8
5. Foreign Body Aspiration
Foreign body aspiration (FBA) is a life-threatening emergency most common in children aged 1-3 years due to the oral phase of development, small airway caliber, and immature swallowing coordination. The most commonly aspirated objects include peanuts, other nuts and seeds, small food items (grapes, hot dogs, carrots), and small toy parts. Organic material causes more severe airway inflammation than inorganic objects.9 10
5.1 Clinical Presentation
| Presentation Phase | Features |
|---|---|
| Acute choking event | Sudden onset of coughing, gagging, stridor, or respiratory distress during eating or play; may witness the event |
| Asymptomatic interval | Hours to days; initial cough subsides as foreign body lodges in one position; child may appear well |
| Complication phase | Recurrent or persistent cough, wheezing (often unilateral), recurrent pneumonia, fever, hemoptysis, lung abscess |
5.2 BLS Management of Choking
Conscious Infant (<1 year) with Severe Airway Obstruction:
- 5 back blows: hold infant face-down along forearm, head lower than trunk, deliver 5 firm back blows between the scapulae with heel of hand
- 5 chest thrusts: turn infant face-up, deliver 5 chest thrusts (same location as CPR compressions) using 2 fingers
- Repeat back blows and chest thrusts until object is expelled or infant becomes unresponsive
- If unresponsive: begin CPR; each time the airway is opened for ventilation, look for the foreign body in the mouth — remove only if visualized; do NOT perform blind finger sweeps in infants/children
Conscious Child (>1 year) with Severe Airway Obstruction:
- Abdominal thrusts (Heimlich maneuver): stand behind child, place fist above umbilicus and below xiphoid, deliver quick inward-upward thrusts
- Repeat until object expelled or child becomes unresponsive
- If unresponsive: begin CPR as above
Mild Obstruction (Effective Cough):
- Encourage coughing; do NOT interfere
- Do NOT perform back blows or abdominal thrusts if the child is coughing effectively, speaking, or breathing
- Monitor closely for deterioration to complete obstruction
5.3 Imaging
| Modality | Utility |
|---|---|
| Chest radiograph (PA and lateral) | First-line imaging; radio-opaque foreign bodies (metal, bone) are directly visible; most aspirated objects in children are radiolucent (food, plastic); indirect signs include unilateral hyperinflation, atelectasis, or mediastinal shift |
| Inspiratory/expiratory films | Expiratory film may show air trapping distal to foreign body (hyperinflated hemithorax that fails to deflate); limited cooperation in young children |
| Bilateral decubitus films | Alternative to expiratory film in young children; dependent lung should normally deflate — failure to deflate suggests ipsilateral air trapping |
| CT chest | Higher sensitivity than plain film; consider if high clinical suspicion with negative radiographs |
| Fluoroscopy | Real-time assessment of diaphragm movement and mediastinal shift; rarely needed |
5.4 Definitive Management
| Scenario | Management |
|---|---|
| Suspected FBA with stable airway | Urgent (not emergent) rigid bronchoscopy under general anesthesia — gold standard for diagnosis and removal |
| Confirmed FBA with respiratory distress | Emergent bronchoscopy |
| Complete airway obstruction unresponsive to BLS | Emergency cricothyrotomy or needle cricothyrotomy (rare in children); emergency bronchoscopy |
| Esophageal foreign body | Rigid esophagoscopy; button batteries in the esophagus require emergent removal (<2 hours) due to risk of caustic necrosis, perforation, and fistula formation |
5.5 Key Points
- Right mainstem bronchus is the most common site of lodging in older children and adults due to its more vertical orientation; in young children, either side may be affected with approximately equal frequency
- Button battery ingestion is a true emergency if lodged in the esophagus — can cause full-thickness esophageal necrosis within 2 hours; honey (10 mL every 10 minutes) may be given en route if battery ingestion was <12 hours ago and child is >12 months old, as it has been shown to reduce tissue injury
- Rigid bronchoscopy is preferred over flexible bronchoscopy for foreign body removal in children because it provides a secure airway, better visualization, and allows passage of larger instruments
- A normal chest radiograph does not exclude foreign body aspiration — sensitivity is only 60-75%; maintain high clinical suspicion based on history9 10
6. Pediatric Upper Airway Emergencies: Differential Diagnosis
| Condition | Age | Onset | Fever | Drooling | Stridor | Cough | Position | Key Features |
|---|---|---|---|---|---|---|---|---|
| Croup | 6 mo–6 yr | Gradual (1-3 days) | Low-grade | No | Inspiratory | Barky | Any | Worse at night; steeple sign |
| Epiglottitis | 2–7 yr (unvaccinated); any age | Rapid (hours) | High | Yes | Inspiratory (muffled) | Minimal | Tripod, sniffing | Toxic appearance; thumb sign; rare since Hib vaccination |
| Bacterial tracheitis | 6 mo–8 yr | Days (after viral URI) | High | Possible | Biphasic | Productive | Any | Toxic, worsening after initial croup treatment; thick tracheal secretions |
| Peritonsillar abscess | >5 yr, adolescents | Days | High | Yes | Possible | Muffled | — | Trismus; uvular deviation; “hot potato” voice |
| Retropharyngeal abscess | 2–4 yr | Days | High | Yes | Possible | — | Neck extension | Neck stiffness; widened prevertebral space on lateral neck XR (>7mm at C2, >14mm at C6) |
| Foreign body | 6 mo–4 yr | Sudden | None (initially) | Possible | Variable | Variable | — | Witnessed choking event; unilateral wheeze |
| Angioedema | Any | Minutes to hours | None | Possible | Possible | None | — | Lip/tongue/periorbital swelling; may be allergic or hereditary |
Bjornson CL, Johnson DW. “Croup in Children.” CMAJ. 2013;185(15):1317-1323. DOI: 10.1503/cmaj.121645 ↩︎ ↩︎ ↩︎
Zoorob R, Sidani M, Murray J. “Croup: An Overview.” Am Fam Physician. 2011;83(9):1067-1073. URL: https://www.aafp.org/pubs/afp/issues/2011/0501/p1067.html ↩︎ ↩︎
Ralston SL, Lieberthal AS, Meissner HC, et al. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics. 2014;134(5):e1474-e1502. DOI: 10.1542/peds.2014-2742 ↩︎ ↩︎ ↩︎
Florin TA, Plint AC, Zorc JJ. “Viral Bronchiolitis.” Lancet. 2017;389(10065):211-224. DOI: 10.1016/S0140-6736(16)30951-5 ↩︎ ↩︎ ↩︎
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2024. URL: https://ginasthma.org/gina-reports/ ↩︎
Expert Panel Working Group of the National Heart, Lung, and Blood Institute. “2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.” J Allergy Clin Immunol. 2020;146(6):1217-1270. DOI: 10.1016/j.jaci.2020.10.003 ↩︎
Shaker MS, Wallace DV, Golden DBK, et al. “Anaphylaxis — A 2020 Practice Parameter Update, Systematic Review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Analysis.” J Allergy Clin Immunol. 2020;145(4):1082-1123. DOI: 10.1016/j.jaci.2020.01.017 ↩︎ ↩︎
Cardona V, Ansotegui IJ, Ebisawa M, et al. “World Allergy Organization Anaphylaxis Guidance 2020.” World Allergy Organ J. 2020;13(10):100472. DOI: 10.1016/j.waojou.2020.100472 ↩︎ ↩︎
Fidkowski CW, Zheng H, Firth PG. “The Anesthetic Considerations of Tracheobronchial Foreign Bodies in Children: A Literature Review of 12,979 Cases.” Anesth Analg. 2010;111(4):1016-1025. DOI: 10.1213/ANE.0b013e3181ef3e9c ↩︎ ↩︎
Committee on Injury, Violence, and Poison Prevention. “Prevention of Choking Among Children.” Pediatrics. 2010;125(3):601-607. DOI: 10.1542/peds.2009-2862 ↩︎ ↩︎